Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure
- PMID: 27148465
- PMCID: PMC4842367
- DOI: 10.1155/2016/3942605
Progenitor Hematopoietic Cells Implantation Improves Functional Capacity of End Stage Coronary Artery Disease Patients with Advanced Heart Failure
Abstract
Background. Proangiogenic Hematopoietic Cells (PHC) which comprise diverse mixture of cell types are able to secrete proangiogenic factors and interesting candidate for cell therapy. The aim of this study was to seek for benefit in implantation of PHC on functional improvement in end stage coronary artery disease patients with advanced heart failure. Methods. Patients with symptomatic heart failure despite guideline directed medical therapy and LVEF less than 35% were included. Peripheral blood mononuclear cells were isolated, cultivated for 5 days, and then harvested. Flow cytometry and cell surface markers were used to characterize PHC. The PHC were delivered retrogradely via sinus coronarius. Echocardiography, myocardial perfusion, and clinical and functional data were analyzed up to 1-year observation. Results. Of 30 patients (56.4 ± 7.40 yo) preimplant NT proBNP level is 5124.5 ± 4682.50 pmol/L. Harvested cells characterized with CD133, CD34, CD45, and KDR showed 0.87 ± 0.41, 0.63 ± 0.66, 99.00 ± 2.60, and 3.22 ± 3.79%, respectively. LVEF was improved (22 ± 5.68 versus 26.8 ± 7.93, p < 0.001) during short and long term observation. Myocardial perfusion significantly improved 6 months after treatment. NYHA Class and six-minute walk test are improved during short term and long term follow-up. Conclusion. Expanded peripheral blood PHC implantation using retrograde delivery approach improved LV systolic function, myocardial perfusion, and functional capacity.
Figures




Similar articles
-
G-CSF stimulation and coronary reinfusion of mobilized circulating mononuclear proangiogenic cells in patients with chronic ischemic heart disease:five-year results of the TOPCARE-G-CSF trial.Cell Transplant. 2012;21(11):2325-37. doi: 10.3727/096368912X654957. Epub 2012 Sep 7. Cell Transplant. 2012. PMID: 22963750 Clinical Trial.
-
Long-Term Outcome of Intra-Myocardial Injection of Autologous Bone Marrow Mononuclear Cells Combined with Isolated Coronary Artery Bypass Grafting for Patients with Chronic Ischemic Heart Failure.Heart Surg Forum. 2016 Jun 24;19(3):E131-8. doi: 10.1532/hsf.1505. Heart Surg Forum. 2016. PMID: 27355149 Clinical Trial.
-
Functional recovery of patients with ischemic cardiomyopathy treated with coronary artery bypass surgery and concomitant intramyocardial bone marrow mononuclear cell implantation--a long-term follow-up study.Vojnosanit Pregl. 2015 Mar;72(3):225-32. doi: 10.2298/vsp140109071t. Vojnosanit Pregl. 2015. PMID: 25958473 Clinical Trial.
-
Cardiac resynchronisation therapy in patients with end-stage heart failure--long-term follow-up.Kardiol Pol. 2008 Jan;66(1):19-26; discussion 27. Kardiol Pol. 2008. PMID: 18266184
-
Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.Dan Med Bull. 2001 Nov;48(4):199-210. Dan Med Bull. 2001. PMID: 11767125 Review.
Cited by
-
Of Cytometry, Stem Cells and Fountain of Youth.Stem Cell Rev Rep. 2017 Aug;13(4):465-481. doi: 10.1007/s12015-017-9733-5. Stem Cell Rev Rep. 2017. PMID: 28364326 Review.
-
Myocardial Ischemia and Mobilization of Circulating Progenitor Cells.J Am Heart Assoc. 2018 Feb 20;7(4):e007504. doi: 10.1161/JAHA.117.007504. Epub 2018 Feb 10. J Am Heart Assoc. 2018. PMID: 31898922 Free PMC article.
-
An Alternative Prediction Equation for Evaluation of Six-Minute Walk Distance in Stable Coronary Artery Disease Patients.Front Physiol. 2022 Mar 31;13:844847. doi: 10.3389/fphys.2022.844847. eCollection 2022. Front Physiol. 2022. PMID: 35432004 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous